Administering a CXCR4 antagonist to PDAC-bearing mice results in the rapid accumulation of CTLs, the arrest of tumour growth, and increased tumour sensitivity to the anti-PD-L1 antibody [15]. This evidence concerns the gene CD274 and neoplasm.